CANCER CHEMOTHERAPY ASSOCIATED NAUSEA AND VOMITING THERAPEUTICS MARKET ANALYSIS

Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Type (Acute CINV, Delayed CINV, Anticipatory nausea and emesis and Breakthrough CINV/Refractory CINV), By Drug Class (Dopamine Receptor Antagonists (Metoclopramide, Chlorpromazine, Prochlorperazine, Haloperidol, Droperidol and Others), Serotonin (5-HT3) receptor Antagonists (Ondansetron, Granisetron, Palonosetron, Dolasetron and others), Substance P/NK-1 Antagonists (Aprepitant, Fosaprepitant, Netupitant, and Others), Corticosteroids (Dexamethasone and Methylprednisolone) and others), By Route of Administration (Oral, Parenteral and Transdermal Patch), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jun 2023
Code : CMI5823
Pages :266
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market - Key Players

Major players operating in the global cancer chemotherapy associated nausea and vomiting therapeutics market are Eisai Co., Ltd., Pharmanovia, Novartis AG, Merck & Co., Inc., Helsinn Healthcare SA, Dr. Reddy’s Laboratories Ltd., Validus Pharmaceuticals LLC, LGM Pharma, Astellas Pharma Inc., AdvaCare Pharma, Norgine, PV Pharma, Fresenius Kabi, Lupin, Hetero Healthcare Limited., Sino Biopharmaceutical Limited, Glenmark Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd, OPKO Health, Inc., Weefsel Pharma, Pfizer Inc., Rosemont Pharmaceuticals Ltd., Starton Therapeutics.

Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market Report Snapshots